During the past decades, studies have examined different pathways of inflammation in patients with cardiovascular disease (CVD), including the proinflammatory cytokines interleukin (IL)-1, IL-6 and IL-8.1 3 4 Targeted therapy against IL-1 in patients with CVD has been explored based on the role of IL-1 as an important regulator of downstream cytokine activation, including IL-6. Here, IL6 is linked to cardiovascular disorder.